TONIX PHARMACEUTICALS

NASDAQ: TNXP

HQ: Chatham, NJ

investor.relations@tonixpharma.com

MANAGEMENT TEAM

Seth Lederman, MD
Co-Founder, CEO & Chairman

Gregory Sullivan, MD
Chief Medical Officer

Bradley Saenger, CPA
Chief Financial Officer

Jessica Morris
Chief Operating Officer

MAIN U.S. OFFICES

New Jersey Office (Corporate & Tonix Medicines Headquarters)
26 Main Street - Ste 101
Chatham, NJ 07928

Research and Development Center (RDC)
431 Aviation Way
Frederick, MD 21701

Advanced Development Center (ADC)
259 Samuel Barnet Blvd
New Bedford Business Park
North Dartmouth, MA 02745

www.tonixpharma.com
@TonixPharma

Version P0534 February 26, 2024 (Doc 1388)

What We Do

Tonix is a biopharmaceutical company that commercializes, develops, discovers and licenses therapeutics to treat and prevent human disease and alleviate suffering. **Tonix is focused on filing the NDA for TNX-102 SL (sublingual cyclobenzaprine) with the FDA for the management of fibromyalgia in the 2nd half of 2024. The NDA is supported by two positive Phase 3 trials**

Leveraging the expertise of the Company's leaders, Tonix's strategy includes:

- **Progressing our curated portfolio of product candidates** in development, including small molecule drugs and biologics, with a focus on central nervous system disorders
- **Marketing FDA-approved products** through our expanding in-house capabilities and expertise in the migraine and pain space
- **Partnering strategically** with government institutions, other biotech companies and world-class academic organizations to reduce internal spend and bring innovative therapeutics to market faster

Key Clinical Candidates

TNX-102 SL
Fibromyalgia

TNX-102 SL is a non-opioid, non-addictive treatment in development for the management of fibromyalgia (FM) and other CNS indications such as FM-type Long COVID and Acute Stress Disorder (ASD)

TNX-1300
Cocaine Intoxication

TNX-1300 is a recombinant protein which rapidly degrades cocaine in the bloodstream and has received FDA Breakthrough Therapy Designation as well as a Cooperative Agreement Grant from the National Institute on Drug Abuse (NIDA)

TNX-2900
Prader-Willi Syndrome

TNX-2900 is a novel formulation of intranasal oxytocin potentiated with magnesium in development for the treatment of Prader-Willi Syndrome, a rare genetic disorder, and has received FDA Orphan Drug Designation

TNX-1500
Transplant Rejection

TNX-1500 is a next generation anti-CD40L mAb designed to preserve efficacy without risk of thrombosis in development for the prevention of organ transplant rejection and autoimmune conditions

Development Pipeline: Key Product Candidates

Using our integrated development engine, we advance innovative programs toward FDA approval

Molecule*	Indication	Phase 1	Phase 2	Phase 3	NDA Submission
TNX-102 SL Cyclobenzaprine HCl Protectic® Sublingual Tablets	Fibromyalgia	*Positive Phase 3 Topline Results Reported 4Q'23*			***Expected 2H'24***
	Long COVID	*Phase 2 Topline Results Reported 3Q'23*			
	Acute Stress Disorder	*Phase 2 Study Start Expected 2Q'24*			
TNX-1300 Cocaine Esterase *NIDA Funded & Breakthrough Therapy Designation*	Cocaine Intoxication	*Phase 2 Study Start Expected 1Q'24*			
TNX-2900 Intranasal Potentiated Oxytocin *FDA Orphan Drug Designation*	Prader-Willi Syndrome	*Phase 2 Ready*			
TNX-1500 Anti-CD40L mAb	Organ Transplant Rejection/ Autoimmune Conditions	*Phase 1 Study Ongoing*			***Phase 1 data expected 3Q'24***

**All of Tonix's product candidates are investigational new drugs or biologics and have not been approved for any indication. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially.*

- ***Filing NDA for the management of fibromyalgia supported by two positive Phase 3 trials expected 2H'24***
- Two CNS programs (Cocaine Intoxication and ASD) expected to begin enrolling in Phase 2 trials in 1H'24
- TNX-1500 Phase 1 study enrollment and dosing complete; Phase 1 data expected 3Q'24

Our Commercial Strategy

We market two FDA-approved products for the treatment of acute migraine

	Zembrace® SymTouch®	*Tosymra®*
Indication	Acute migraine with or without aura in adults	Acute migraine with or without aura in adults
Delivery	Sumatriptan injection, 3 mg	Sumatriptan nasal spray, 10 mg
Design	Only branded sumatriptan autoinjector promoted in the U.S. Designed for ease of use and favorable tolerability with low 3 mg dose	Formulated with a permeation enhancer (Intravail® technology) that provides rapid and efficient absorption of sumatriptan Pharmacokinetically equivalent to 4 mg subcutaneous sumatriptan
Patent Protection	Patent protection until 2036	Patent protection until 2031